309.87
-1.33 (-0.43%)
| Previous Close | 311.20 |
| Open | 307.32 |
| Volume | 681,330 |
| Avg. Volume (3M) | 1,179,530 |
| Market Cap | 30,418,538,496 |
| Price / Earnings (TTM) | 28.77 |
| Price / Earnings (Forward) | 21.01 |
| Price / Sales | 5.69 |
| Price / Book | 11.57 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 22.02% |
| Operating Margin (TTM) | 22.93% |
| Diluted EPS (TTM) | 11.01 |
| Quarterly Revenue Growth (YOY) | 3.90% |
| Quarterly Earnings Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 78.58% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | 758.81 M |
| Levered Free Cash Flow (TTM) | 588.83 M |
| Return on Assets (TTM) | 11.61% |
| Return on Equity (TTM) | 40.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Waters Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 98.23% |
| 52 Weeks Range | ||
| Median | 350.00 (12.95%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 23 Feb 2026 | 350.00 (12.95%) | Hold | 327.78 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |